Scholarlink

Objective <p>Patients receiving endocrine therapy after breast cancer surgery exhibit a high incidence of endometrial lesions, yet corresponding measures to prevent recurrence of lesions remain inadequate. This study aims to investigate the correlation between endometrial lesion recurrence and multiple factors, with the goal of reducing recurrence risks and improving patient outcomes.</p> Methods <p>Retrospective analysis of clinical data of 314 patients with breast cancer who underwent hysteroscopy after surgery was reviewed from August 2014 to August 2024. The status of ultrasound follow-up in these patients after hysteroscopic treatment was retrospectively reviewed to determine the recurrence outcomes. The column chart predicting endometrial lesion recurrence risk was constructed by R language. The Kaplan–Meier Curve and Log-Rank Test were employed to further analyze the correlation between medication duration and endometrial recurrence risk.</p> Results <p>The recurrence rate of endometrial lesions in toremifene (TOR) group was significantly higher (78.6% VS control group: 12.4%), and the usage of TOR, age, non-benign endometrial lesions, increased endometrial thickness, increased size of polyps, history of adenomyosis and uterine fibroids were significantly correlated with the recurrence rate of endometrial lesions. Survival analysis showed a median recurrence-free survival time of 49&#xa0;months for patients using TOR.</p> Conclusion <p>Patients using TOR are prone to endometrial lesions, especially young patients who use TOR drugs for a long time. The larger the polyp and the thicker the endometrium, the higher the risk of recurrence of endometrial lesions. Furthermore, enhanced endometrial monitoring is recommended during the initial four-year high-risk period.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Study on the Recurrence Factors of Endometrial Lesions in Patients Undergoing Hysteroscopy After Breast Cancer Surgery

  • 期刊论文

  • 发表日期：

    2026年2月25日

查看全文
  • Xinyue Chen,
  • Qian Zhang,
  • Rongying Ou

摘要

Objective

Patients receiving endocrine therapy after breast cancer surgery exhibit a high incidence of endometrial lesions, yet corresponding measures to prevent recurrence of lesions remain inadequate. This study aims to investigate the correlation between endometrial lesion recurrence and multiple factors, with the goal of reducing recurrence risks and improving patient outcomes.

Methods

Retrospective analysis of clinical data of 314 patients with breast cancer who underwent hysteroscopy after surgery was reviewed from August 2014 to August 2024. The status of ultrasound follow-up in these patients after hysteroscopic treatment was retrospectively reviewed to determine the recurrence outcomes. The column chart predicting endometrial lesion recurrence risk was constructed by R language. The Kaplan–Meier Curve and Log-Rank Test were employed to further analyze the correlation between medication duration and endometrial recurrence risk.

Results

The recurrence rate of endometrial lesions in toremifene (TOR) group was significantly higher (78.6% VS control group: 12.4%), and the usage of TOR, age, non-benign endometrial lesions, increased endometrial thickness, increased size of polyps, history of adenomyosis and uterine fibroids were significantly correlated with the recurrence rate of endometrial lesions. Survival analysis showed a median recurrence-free survival time of 49 months for patients using TOR.

Conclusion

Patients using TOR are prone to endometrial lesions, especially young patients who use TOR drugs for a long time. The larger the polyp and the thicker the endometrium, the higher the risk of recurrence of endometrial lesions. Furthermore, enhanced endometrial monitoring is recommended during the initial four-year high-risk period.